AX vs HASI

The Advanced Deterministic Scorecard reveals a mixed financial profile: the Piotroski F-Score of 4/9 indicates borderline stable financial health, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics like a 50.8% operating margin and consistent earnings beats, weak revenue growth and lack of key financial data constrain confidence. The stock trades above the Graham Number of $88.69 at $91.75, implying a slight premium, but remains below the analyst target of $103.25. Bearish insider activity and a weak technical trend offset solid historical performance and favorable sector-relative valuation.

HASI exhibits significant fundamental weakness, highlighted by a weak Piotroski F-Score of 3/9 and a current price ($41.77) that trades at a massive premium to both its Graham Number ($25.34) and Intrinsic Value ($9.87). While analysts maintain a 'strong_buy' rating and the stock has seen strong 1-year price appreciation, the underlying data reveals a critical dividend payout ratio of 119.15% and severe Q/Q revenue contraction of -124.88%. The combination of high debt/equity (1.94) and deteriorating growth metrics suggests the current valuation is speculative and unsupported by deterministic health scores.